UCB SA (OTCMKTS:UCBJF) Sees Significant Drop in Short Interest

UCB SA (OTCMKTS:UCBJF) saw a large drop in short interest in the month of September. As of September 30th, there was short interest totalling 419,400 shares, a drop of 22.6% from the September 15th total of 542,000 shares. Based on an average daily trading volume, of 100 shares, the short-interest ratio is currently 4,194.0 days.

UCB Stock Performance

Shares of UCBJF stock opened at $179.05 on Monday. UCB has a 1 year low of $69.70 and a 1 year high of $180.00. The company’s fifty day simple moving average is $174.76 and its two-hundred day simple moving average is $147.57. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.19 and a quick ratio of 0.78.

UCB Company Profile

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.